Piper Jaffray Cuts Price Target on Nxstage Medical (NXTM) Following Mixed 4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
February 10, 2016 8:04 AM ESTLAWRENCE, Mass., Feb. 10, 2016 /PRNewswire/ -- Â
Highlights:
Full-Year Revenue Increases to $336 million, up 11% from 2014 Full-Year Home Revenue Increases to $183 million, up 16% from 2014 Full-Year Operating Income from Products Business Increases to $9 million Company Highlights Significant Product Introductions for the Next Three Years For Third Consecutive Year, Company Targets 15% Annual Home Revenue GrowthNxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported record revenue for the fourth quarter and fiscal year ended... More
